Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY27 Results Analysis: PAT Jumps 27%, EBITDA Margin Compresses 220 bps
Sun Pharmaceutical Industries Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 15,300.00 Cr (+10.50% YoY) and PAT growth of +27.00% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 15,300.00 Cr (+10.50% YoY) |
| PAT (Q1) | Rs. 2,895.00 Cr (+27.00% YoY) |
| EBITDA margin | 28.90% (-220 bps YoY) |
| EPS (Q1) | Rs. 12.10 (+27.40% YoY) |
| Market cap | Rs. 477,671.17 Cr |
| CMP | Rs. 1,990.50 |
Quarter Snapshot
Q1 revenue growth of 10.5% YoY exceeded management's high single-digit guidance, driven by strong India performance (+16%) and Innovative Medicines (+12.8% USD). PAT grew 27% YoY, though EBITDA margin contracted 220bps due to cost pressures. US generics remained weak (-9.7% USD). The Organon acquisition is on track for early 2027 closing, providing a long-term catalyst. Overall, a solid quarter with a revenue beat but margin compression warrants caution.
Key Investment Insights
Key Positives
- Revenue grew 10.5% YoY to Rs.152,999 Mn, exceeding management's high single-digit guidance
- PAT grew 27.0% YoY to Rs.28,948 Mn, aided by lower exceptional items
- India formulations grew 16.0% YoY, gaining market share to 8.5% (up 30 bps)
- Innovative Medicines segment grew 12.8% YoY in USD, now 21.9% of sales
- Normalized PAT (ex-exceptionals) grew 3.1% YoY to Rs.30,894 Mn
- Organon acquisition on track with stockholder approval received and closing expected early 2027
Risk Factors
- US formulations declined 9.7% YoY in USD due to pricing pressure and compliance issues
- EBITDA margin contracted 220 bps YoY to 28.9%, driven by higher employee costs and acquisition expenses
- Employee benefits expense grew 15.2% YoY, outpacing revenue growth
- Finance costs increased 33.3% YoY, reflecting higher interest burden
- Effective tax rate of 29.0% exceeded the expected 25.168% due to non-deductible exceptional items
- R&D spend at 5.4% of sales was below the 6-7% guidance range
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.